Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Engine Biosciences Raises $10 Million for AI Drug Discovery from Asian/US Investors

publication date: Jan 31, 2018

Engine Biosciences, a San Francisco-Singapore startup, raised $10 million in seed capital to develop its artificial intelligence/genomics drug development platform. The company claims its platform, which combines massively parallel biological experimentation with artificial intelligence, provides faster and deeper understanding of biologic interactions, offering new insights into drug development. The seed round was co-led by California's DHVC and Shanghai's 6 Dimensions Capital (the entity formed by a merger between Frontline Bioventures and WuXi Healthcare Ventures). More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital